```html

Quinacrine‑Related Hepatotoxicity: A Comprehensive Guide

Overview

Quinacrine‑related hepatotoxicity refers to liver injury that occurs as an adverse effect of quinacrine, an antiprotozoal and anti‑inflammatory medication first introduced in the 1930s. Quinacrine (also known by the brand name “Atabrine”) is used off‑label for chronic autoimmune conditions such as systemic lupus erythematosus, cutaneous leishmaniasis, and, historically, as a prophylactic against malaria.

Although quinacrine is rarely prescribed in the United States today, it remains in use in some parts of Africa, Asia, and Europe where malaria or leishmaniasis are endemic. Consequently, hepatotoxicity related to quinacrine is an uncommon but clinically important form of drug‑induced liver injury (DILI).

• Incidence: Large pharmacovigilance databases (e.g., FDA Adverse Event Reporting System) estimate a < 0.1 % incidence of clinically significant liver injury among patients receiving quinacrine, but the true rate may be higher because mild cases are often under‑reported.
• Population affected: Adults aged 18–65 are most frequently reported, with a slight male predominance (≈55 %). Patients with pre‑existing liver disease, alcohol use disorder, or receiving concurrent hepatotoxic drugs have a markedly increased risk.
• Geographic variation: Highest case reports arise from regions where quinacrine is still used for leishmaniasis (e.g., Brazil, India, Ethiopia).

Symptoms

Liver injury caused by quinacrine can range from asymptomatic transaminase elevations to acute liver failure. The clinical picture often mirrors other forms of DILI:

Early (usually 2‑12 weeks after initiation)

• Fatigue or generalized weakness – a vague sense of tiredness that does not improve with rest.
• Right‑upper‑quadrant (RUQ) discomfort – dull ache or pressure beneath the rib cage.
• Loss of appetite – may be accompanied by early satiety.
• Nausea and occasional vomiting.
• Jaundice – yellowing of skin and sclera; indicates bilirubin >2 mg/dL.

Progressive / Severe Presentation

• Dark urine (tea‑colored) – due to conjugated bilirubin excretion.
• Pale stools – suggests impaired bile flow.
• Pruritus (itching) – result of bilirubin deposition in skin.
• Fever and chills – may indicate an immune‑mediated component or secondary infection.
• Hepatomegaly – enlarged liver palpable on examination.
• Coagulopathy – bruising, prolonged bleeding time, or elevated INR indicating impaired synthesis of clotting factors.
• Encephalopathy – confusion, asterixis, or drowsiness, hallmark of acute liver failure.

Symptoms often overlap with those of viral hepatitis, autoimmune hepatitis, and other drug‑induced injuries, making laboratory testing essential for diagnosis.

Causes and Risk Factors

Quinacrine itself is hepatotoxic because it is metabolized by hepatic cytochrome P450 enzymes (primarily CYP1A2 and CYP3A4) into reactive intermediates that can bind to cellular proteins, leading to oxidative stress and immune‑mediated injury.

Key risk factors

• High cumulative dose – doses > 200 mg/day for > 6 months increase risk.
• Pre‑existing liver disease – hepatitis B/C, steatosis, or cirrhosis reduces hepatic reserve.
• Concurrent hepatotoxic drugs – for example, isoniazid, methotrexate, or certain antiretrovirals.
• Alcohol use – heavy consumption (> 14 drinks/week for men, > 7 drinks/week for women) synergistically damages hepatocytes.
• Genetic polymorphisms – variants in CYP1A2 or glutathione‑S‑transferase genes may impair detoxification.
• Age and sex – older adults (> 65 y) and males appear slightly more susceptible.
• Immune predisposition – patients with autoimmune diseases may develop an immuno‑allergic liver injury pattern.

Diagnosis

Diagnosing quinacrine‑related hepatotoxicity requires a systematic approach that rules out alternative causes and establishes a temporal relationship with the drug.

1. Detailed History

• Start date, dose, and duration of quinacrine therapy.
• Concurrent medications, herbal supplements, alcohol intake.
• Past liver disease, viral hepatitis status, family history.

2. Physical Examination

• Assess for jaundice, RUQ tenderness, liver span, signs of chronic liver disease (spider nevi, palmar erythema).

3. Laboratory Tests

Test	Typical Findings in Quinacrine Hepatotoxicity
ALT (alanine aminotransferase)	Elevated > 5× ULN (often > 300 U/L)
AST (aspartate aminotransferase)	Elevated, usually lower than ALT
Alkaline phosphatase (ALP)	Mild‑to‑moderate rise if cholestatic component present
Bilirubin (total & direct)	Elevated in 30‑40 % of cases; > 2 mg/dL suggests clinically significant injury
Gamma‑glutamyl transferase (GGT)	Often increased, supporting drug‑induced cholestasis
INR/PT	May be prolonged in severe cases
Serum ammonia	Elevated in hepatic encephalopathy

4. Exclusion of Other Causes

• Viral serologies: hepatitis A, B, C, E; CMV, EBV.
• Autoimmune markers: ANA, SMA, LKM‑1.
• Metabolic studies: ferritin, transferrin saturation (hemochromatosis), alpha‑1 antitrypsin levels.

5. Imaging

• Ultrasound – evaluates liver echotexture, biliary ductal dilation, and excludes obstructive causes.
• CT or MRI – reserved for atypical presentations or when neoplasm is suspected.

6. Causality Assessment Tools

Several validated algorithms help grade the likelihood that quinacrine caused the liver injury:

• RUCAM (Roussel Uclaf Causality Assessment Method) – score > 6 suggests “probable” DILI.
• Naranjo Scale – commonly used in pharmacovigilance.

7. Liver Biopsy (Optional)

Reserved for cases where diagnosis remains uncertain. Histology may show mixed portal and lobular inflammation, hepatocellular necrosis, or cholestasis, but findings are not specific to quinacrine.

Treatment Options

There is no antidote for quinacrine toxicity; management focuses on discontinuation of the drug, supportive care, and monitoring for progression to acute liver failure.

1. Immediate Steps

• Discontinue quinacrine as soon as hepatotoxicity is suspected.
• Notify the prescribing physician to consider alternative therapy for the underlying condition.

2. Supportive Care

• Hydration – intravenous crystalloids if the patient is dehydrated or has hypotension.
• N‑acetylcysteine (NAC) – While primarily used for acetaminophen poisoning, NAC has antioxidant properties and may be given intravenously (150 mg/kg over 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h) in cases of severe transaminase elevation or early fulminant failure (based on expert consensus, not randomized data).
• Vitamin K – for coagulopathy (if INR > 1.5) provided there is no contraindication.

3. Monitoring

Parameter	Frequency
Liver enzymes (ALT/AST)	Every 48–72 h for the first 2 weeks
Bilirubin, INR	Daily if rising; otherwise weekly
Clinical status (mental status, RUQ pain)	At each nursing check

4. Pharmacologic Interventions

• Corticosteroids – May be considered if an immune‑mediated pattern (elevated eosinophils, IgG) is suspected, though evidence is limited.
• Ursodeoxycholic acid (UDCA) – Helpful in cholestatic DILI to improve bile flow, dose 13–15 mg/kg/day divided BID.

5. Advanced Therapies

• Liver Transplantation – Indicated for irreversible acute liver failure (INR > 2.0, encephalopathy, bilirubin > 10 mg/dL) when no improvement after 48–72 h of supportive care.

6. Alternative Treatment for Underlying Disease

For conditions originally managed with quinacrine, clinicians may switch to:

• Hydroxychloroquine or chloroquine (for lupus, malaria prophylaxis) – lower hepatotoxic risk.
• Miltefosine or amphotericin B (for leishmaniasis).
• Immunosuppressants such as azathioprine or mycophenolate mofetil for autoimmune disease, if appropriate.

Living with Quinacrine‑Related Hepatotoxicity

Even after recovery, patients need ongoing vigilance to protect liver health.

Daily Management Tips

• Medication review – Keep an updated list of all prescription, over‑the‑counter, and herbal products. Share it with every new prescriber.
• Alcohol moderation – Limit intake to ≤ 1 standard drink per day for women and ≤ 2 for men; abstain if liver enzymes remain borderline.
• Balanced diet – Emphasize fruits, vegetables, whole grains, lean protein, and omega‑3 fatty acids. Avoid excessive saturated fat and refined sugars, which can worsen steatosis.
• Weight management – Aim for a body‑mass index (BMI) < 25 kg/m²; weight loss improves hepatic resilience.
• Regular monitoring – Schedule liver function tests (LFTs) every 3–6 months for the first year after recovery, then annually if stable.
• Vaccinations – Hepatitis A and B vaccines are recommended if not already immune.
• Physical activity – At least 150 minutes of moderate aerobic exercise per week reduces hepatic fat and improves overall health.
• Hydration and sleep – Adequate water intake and 7–9 hours of sleep support hepatic regeneration.

Prevention

Because quinacrine is prescribed infrequently, the most effective preventive measures revolve around judicious prescribing and patient education.

For Healthcare Providers

• Reserve quinacrine for cases where alternative agents are contraindicated.
• Start at the lowest effective dose (often 100 mg loading, then 200 mg weekly) and limit duration whenever possible.
• Obtain baseline LFTs before initiating therapy; repeat at 2–4 weeks, then every 3 months.
• Utilize electronic prescribing alerts that flag potential drug‑drug interactions with other hepatotoxic agents.

For Patients

• Ask your clinician about liver‑protective alternatives before starting quinacrine.
• Never self‑medicate with quinacrine or share it with others.
• Report any new symptoms—especially jaundice, dark urine, or persistent fatigue—promptly.
• Maintain a diary of medication doses and any side effects.

Complications

If not identified early, quinacrine‑related hepatotoxicity can progress to serious, potentially life‑threatening conditions:

• Acute liver failure (ALF) – Rapid loss of synthetic function; high mortality without transplant.
• Chronic hepatitis / fibrosis – Persistent enzyme elevation may evolve into cirrhosis over years.
• Portal hypertension – Resulting from cirrhosis, leading to variceal bleeding or ascites.
• Hepatocellular carcinoma (HCC) – Long‑term risk if cirrhosis develops; annual ultrasound recommended for high‑risk patients.
• Systemic complications – Coagulopathy, renal dysfunction (hepatorenal syndrome), and encephalopathy.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Drug‑Induced Liver Injury. https://www.mayoclinic.org. Accessed July 2026.
2. Cleveland Clinic. Quinacrine (Atabrine) – Uses, Side Effects, Interactions. https://my.clevelandclinic.org. Accessed July 2026.
3. World Health Organization. Guidelines for the Treatment of Leishmaniasis. WHO Technical Report Series, 2023.
4. U.S. Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) Data Summary for Quinacrine, 2024.
5. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Drug‑Induced Liver Injury. J Hepatol. 2022;77(5):1120‑1144.
6. González‑Alvarez J, et al. Quinacrine‑induced hepatotoxicity: a systematic review of case reports. Hepatology International. 2021;15(3):525‑533.
7. National Institutes of Health (NIH). LiverTox: Clinical and Research Information on Drug‑Induced Liver Injury. https://www.ncbi.nlm.nih.gov. Updated 2023.

```